Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard(Foundation Medicine (United States)), Pasi A. Jänne(Harvard University), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Kathryn F. Mileham(Levine Cancer Institute), Hatim Husain(University of California, San Diego), Kenneth S. Thress(AstraZeneca (United States)), Michael S. Rabin(Dana-Farber Cancer Institute), Daniel B. Costa(Beth Israel Deaconess Medical Center), Philip Tracy(Tufts University), Cloud P. Paweletz(Massachusetts General Hospital), Amanda J. Redig(Brigham and Women's Hospital), Lynette M. Sholl(Brigham and Women's Hospital), Yuebi Hu(Dana-Farber Cancer Institute), David J. Kwiatkowski(Brigham and Women's Hospital), Nora Feeney(Dana-Farber Cancer Institute)
Cited by 689
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k